Table 5: Compare the mean of NCV in treated patients with Carbamazepine by type of nerves.
|
Type of nerves |
Drugs |
Mean |
P - value |
|
Median
|
Carbamazepine in baseline |
52.4 |
0.004
|
|
Control |
58.7 |
||
|
Median
|
Carbamazepine in baseline |
52.4 |
0.028
|
|
Carbamazepine six month late |
50.6 |
||
|
Ulnar
|
Carbamazepine in baseline |
50.6 |
0.0039
|
|
Control |
50.8 |
||
|
Ulnar
|
Carbamazepine in baseline |
50.6 |
0.041
|
|
Carbamazepine six month late |
48.7 |
||
|
Sural
|
Carbamazepine in Baseline |
48.1 |
0.006
|
|
Control |
50.6 |
||
|
Sural
|
Carbamazepine in baseline |
50.6 |
0.03
|
|
Carbamazepine six month late |
48.04 |
||
|
Peroneal
|
Carbamazepine in baseline |
46.5 |
0.0286
|
|
Control |
46.4 |
||
|
Peroneal |
Carbamazepine in baseline |
46.5 |
0.037 |
|
Carbamazepine six month late |
46.3 |